MYC controls STING levels to downregulate inflammatory signaling in breast cancer cells upon DNA damage.
Ontology highlight
ABSTRACT: Amplification of the MYC proto-oncogene is frequently observed in various cancer types, including triple-negative breast cancer (TNBC). Emerging evidence suggests that suppression of local antitumor immune responses by MYC, at least in part, explains the tumor-promoting effects of MYC. Specifically, MYC upregulation was demonstrated to suppress the tumor-cell intrinsic activation of a type I interferon response and thereby hamper innate inflammatory signaling, which may contribute to the disappointing response to immunotherapy in patients with TNBC. In this study, we show that MYC interferes with protein expression and functionality of the STING pathway. MYC-mediated STING downregulation in BT-549 and MDA-MB-231 TNBC cell lines requires the DNA-binding ability of MYC and is independent of
SUBMITTER: Linstra R
PROVIDER: S-EPMC12166436 | biostudies-literature | 2025 Jun
REPOSITORIES: biostudies-literature
ACCESS DATA